You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimal Hydrophobicity of Lipoid Gene Delivery Agents

    SBC: AVANTI POLAR LIPIDS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cationic lipid-like compounds are commonly used in vitro and in vivo to deliver DNA to cells for the purposes of expressing exogenous genes. A number of clinical trials have indicated the promise of these agents for gene therapy, however lipid-based delivery remains less effective than the alternative viral vectors. Nevertheless, vast improvements have been mad ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Novel fetal heart monitor technology

    SBC: Bioconnexions, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Significant progress has been made in the science of electrocardiography since 1938. Heart rate and biophysical profiles are routinely derived from multi-lead electrocardiograms (ECGs) in animals and humans after birth. In contrast, only limited heart monitoring technologies exist for the fetus. Moreover, available technology fails to satisfy many existing need ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Spinal Fusion Using Adipose Derived Adult Stem Cells

    SBC: Cognate Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Back pain afflicts over 75% of Americans during their lifetime and 2% of the American work force suffers a back injury on the job each year. Spinal fusion is the orthopedic procedure routinely used to treat back pain in patients suffering from degenerative disc disease, spinal stenosis, scoliosis, and spinal fracture; however, procedure failure rates range betw ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  4. MRI Quantification of Postinfarct Myocardial Viability

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is to develop a novel method for MRI quantification of postinfarct myocardial viability. Ultimately, the commercial embodiment of this method will be a software package that will convert a set of 2D cardiac MRI images to a 3D Myocardial Viability Map (MV) with a voxel-by-voxel resolution. In human clinical use, the package woul ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Extended DNA amplification with thermostable chaperons

    SBC: FIDELITY SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this project is to develop a general method of improving the stability and durability of enzymes used in DNA and RNA amplification, sequencing, restriction analysis and ligation. The enzymes to be improved include DNA polymerases, topoisomerases, reverse transcriptases and ligases. In the event this goal can be achieved, broad impacts may result in ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Utility of a Novel Anthracycline Analog in Psoriasis

    SBC: GEM Pharmaceuticals            Topic: N/A

    DESCRIPTION (provided by applicant): Psoriasis is a common immune-mediated disease that affects approximately 2% of the US and European populations and significantly impacts the quality of life. T cells are recognized as primary mediators of the disease and new generation therapies aimed at eliminating reactive T cells or interfering with the immunologic cascade caused by their activation have bee ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Restoration of vestibular hair cells induced by AdMath1

    SBC: GENVEC, INC.            Topic: N/A

    Loss of vestibular hair cells can occur due to a variety of disorders and results in dysfunction of the vestibulo-occular reflex and loss of balance. Bilateral vestibular hypofunction due to aminoglycoside ototoxicity and other means is a devastating and currently untreatable chronic disorder because loss of vestibular hair cells is permanent. To date there is no prosthetic device such as a hearin ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Feasibility study of a double fiber bundle dialyzer

    SBC: MIRIMEDICAL, LLC.            Topic: N/A

    DESCRIPTION (provided by applicant): Efficiency of hemodialysis is currently limited by dialyzer technology. Although new membranes with large surface areas have been developed, the increase in delivered treatment is only marginal. Double dialyzer therapies have been shown to be superior to standard high efficiency/ high flux dialysis treatments; however implementation of double dialyzer therapi ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Assessment of Altered Function in Diabetic Bladder

    SBC: Neurotron, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Diabetic bladder dysfunction (DBD) or diabetic cystopathy is one of the most common and debilitating complications of diabetes mellitus (DM) affecting well over 50% of the patients with either type I or type II diabetes. DBD could affect both the filling and voiding function of the bladder leading to urinary incontinence, poor emptying, high post void residual ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Strategy for Recurrent Spontaneous Abortion

    SBC: Nora, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Recurrent spontaneous abortion (RSA) is a serious medical condition that affects approximately 1-3% of reproductive age women. At present, there is no FDA approved treatment for RSA. We hypothesize that failure to suppress Th1 cytokine production early in pregnancy is a major cause of RSA. We hypothesize that recombinant human granulocyte colony stimulating fa ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government